Momenta Pharmaceuticals, Inc. (MNTA)

[investorgold2002]

Rick shea conf call yesterday - lovenox patent

He talked about their Lovenox patents and how they identified ensuring the very specific structures that we identified that are characteristic to lovenox. We believe TEVA is infringing on those patents

Structure:
I believe he was talking about P8 which Momenta identified for the 1st time.

Structure to Function:
Momenta also identified for the 1st time correlation of P8 to (anti-factor Xa activity) and the Anti-factor IIa activity.

Process Control:
"[0297] Further applications of this method include determining the structural signature of the starting material, e.g. porcine intestinal mucosa heparin. This starting material is isolated in slaughter houses and is often unmonitored by standard quality control techniques. Using the methods described above to ensure that the quality of the starting material, e.g., the structural signature and activity, is sufficient to produce acceptable LMWH preparations. Adding this quality control to the beginning of the procedure so that the starting material is consistent helps to decrease batch-batch variability, and thus decrease the number of rejected batches, saving time and money, and resulting in an improved product."


This patent is identifying the "signature"(which is p8) at the source heparin material and saying selecting batches based on "p8" content would yield desired anti-Xa activity as specified in lovenox monograph.

http://worldwide.espacenet.com/publicationDetails/description?CC=US&NR=2009061411A1&KC=A1&FT=D&date=20090305&DB=EPODOC&locale=en_EP